Seeking Alpha

RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3...

RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3 clinical trial of NeuVax, a cancer immunotherapy targeted for breast cancer patients not eligible for other treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|